BeOne Medicines Reports Strong Q4 & Full Year 2025 Results, Projects Continued Growth in 2026
ONC sits 76% above its 52-week low of $196.45.
Summary
BeOne Medicines reported strong Q4 and full year 2025 financial results, with significant revenue growth and a return to GAAP net income, alongside positive revenue guidance for 2026.
Key Events · Earnings and Guidance · ONC
-
Strong Revenue Growth
Total global revenues increased by 33% to $1.5 billion for Q4 2025 and by 40% to $5.3 billion for the full year 2025 compared to prior-year periods.
-
Return to Profitability
The company achieved GAAP net income of $67 million for Q4 2025 and $287 million for the full year 2025, a significant turnaround from losses in the prior year.
-
Positive 2026 Guidance
BeOne Medicines provided full year 2026 total revenue guidance of $6.2 billion to $6.4 billion, reflecting expectations for continued strong growth.
-
BRUKINSA's Continued Leadership
Global BRUKINSA revenues grew by 38% to $1.1 billion in Q4 and by 49% to $3.9 billion for the full year, establishing it as a global leader in its class.
Analysis · ONC · Life Sciences
BeOne Medicines Ltd. announced robust financial results for the fourth quarter and full year 2025, demonstrating significant revenue growth and a return to profitability. The company's flagship product, BRUKINSA, continues to drive performance, solidifying its position as a global leader in the BTK inhibitor class. The positive full-year 2026 revenue guidance indicates management's confidence in sustained growth and operational leverage. Investors should note the strong free cash flow generation and the advancement of a deep oncology pipeline, which collectively position the company for continued leadership in the global oncology market.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ONC was trading at $345.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $43.7B. The 52-week trading range was $196.45 to $385.22. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.